{
    "clinical_study": {
        "@rank": "117543", 
        "acronym": "Autism", 
        "arm_group": [
            {
                "arm_group_label": "Experimental: Patients", 
                "arm_group_type": "Experimental", 
                "description": "Children who will receive intrathecal autologous stem cells"
            }, 
            {
                "arm_group_label": "Control/Crossover", 
                "arm_group_type": "Other", 
                "description": "We will evaluate with IDEA and CARS scales the control group for 6 months with the possibility to change arms after that time."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether the plasticity of autologous intrathecal\n      hematopoietic cells would improve the neurologic and the social skills of pediatric patients\n      with autism spectrum disorders."
        }, 
        "brief_title": "Autologous Bone Marrow Stem Cells for Children With Autism Spectrum Disorders", 
        "condition": [
            "Autism", 
            "Autism Spectrum"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Autistic Disorder", 
                "Child Development Disorders, Pervasive"
            ]
        }, 
        "detailed_description": {
            "textblock": "There is accumulating evidence that shows that the administration of hematopoietic cells\n      into the brain in the patients with spectrum autism could help in the physiopathology of the\n      illness.\n\n      It has been found that after introducing hematopoietic cells in the subarachnoid space of\n      the spinal cord, these cells may be transported through the cerebrospinal fluid and can be\n      delivered more efficiently to the injured area, when compared to the intravenous route.\n\n      Patients will be stimulated for 3 consecutive days with granulocyte colony stimulating\n      factor (G-CSF) and then their bone marrow will be harvested according to their weight. Bone\n      marrow will be processed in order to obtain CD34+ cells and minimize the amount of red blood\n      cells. An inoculum of 5 to 10mL of stem cells will be infused intrathecally. Patients will\n      be evaluated with two scales \"CARS\" and the \"IDEA\" also we will check the clinical history.\n      On days 0, 30 and 180."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  children with autism spectrum DSM4-TR\n\n        Exclusion Criteria:\n\n          -  Patients with neurodegenerative or autoimmune diseases.\n\n          -  Patients with active infection in any organ or tissue at the time of entering the\n             study, the onset of stimulation with G-CSF or at the procedure.\n\n          -  Patients who do not sign the informed consent form."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "15 Years", 
            "minimum_age": "5 Years"
        }, 
        "enrollment": {
            "#text": "30", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 22, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01740869", 
            "org_study_id": "HE12-021", 
            "secondary_id": "Autism uanl"
        }, 
        "intervention": {
            "arm_group_label": [
                "Experimental: Patients", 
                "Control/Crossover"
            ], 
            "intervention_name": "Stem cells", 
            "intervention_type": "Other", 
            "other_name": [
                "Bone marrow  harvest and aspirate stem cells.", 
                "Intrathecal stem cell aplication autologous stem cells into the spinal canal."
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "autism", 
            "autism spectrum", 
            "stem cells", 
            "children"
        ], 
        "lastchanged_date": "April 11, 2013", 
        "location": {
            "contact": {
                "email": "dr_lauravillarreal@hotmail.com", 
                "last_name": "Laura Villarreal-Martinez, MD", 
                "phone": "+52 81 83 48 61 36", 
                "phone_ext": "413"
            }, 
            "facility": {
                "address": {
                    "city": "Monterrey", 
                    "country": "Mexico", 
                    "state": "Nuevo Leon", 
                    "zip": "64460"
                }, 
                "name": "Hematology Service, Hospital Universitario Dr. Jose E. Gonzalez"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Mexico"
        }, 
        "number_of_arms": "2", 
        "official_title": "Autologous Bone Marrow Stem Cells for Children With Autism Spectrum Disorders", 
        "overall_contact": {
            "email": "dr_lauravillarreal@hotmail.com", 
            "last_name": "Laura Villarreal-Martinez, MD", 
            "phone": "+52 81 83 48 61 36", 
            "phone_ext": "413"
        }, 
        "overall_contact_backup": {
            "email": "consuelomanciasg@gmail.com", 
            "last_name": "Consuelo Mancias-Guerra, MD", 
            "phone": "+52 81 83 48 61 36", 
            "phone_ext": "413"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Mexico: Ethics Committee", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Improvement in IDEA evaluation", 
            "measure": "IDEA Improvement", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "reference": [
            {
                "PMID": "22496609", 
                "citation": "Siniscalco D, Sapone A, Cirillo A, Giordano C, Maione S, Antonucci N. Autism spectrum disorders: is mesenchymal stem cell personalized therapy the future? J Biomed Biotechnol. 2012;2012:480289. doi: 10.1155/2012/480289. Epub 2012 Feb 13. Review."
            }, 
            {
                "PMID": "17597540", 
                "citation": "Ichim TE, Solano F, Glenn E, Morales F, Smith L, Zabrecky G, Riordan NH. Stem cell therapy for autism. J Transl Med. 2007 Jun 27;5:30. Review."
            }, 
            {
                "PMID": "18555135", 
                "citation": "Mehta T, Feroz A, Thakkar U, Vanikar A, Shah V, Trivedi H. Subarachnoid placement of stem cells in neurological disorders. Transplant Proc. 2008 May;40(4):1145-7."
            }, 
            {
                "PMID": "15748871", 
                "citation": "Hayashi T, Iwai M, Ikeda T, Jin G, Deguchi K, Nagotani S, Zhang H, Sehara Y, Nagano I, Shoji M, Ikenoue T, Abe K. Neural precursor cells division and migration in neonatal rat brain after ischemic/hypoxic injury. Brain Res. 2005 Mar 15;1038(1):41-9."
            }, 
            {
                "PMID": "12202033", 
                "citation": "Nakatomi H, Kuriu T, Okabe S, Yamamoto S, Hatano O, Kawahara N, Tamura A, Kirino T, Nakafuku M. Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. Cell. 2002 Aug 23;110(4):429-41."
            }, 
            {
                "PMID": "18632701", 
                "citation": "Goldman SA, Schanz S, Windrem MS. Stem cell-based strategies for treating pediatric disorders of myelin. Hum Mol Genet. 2008 Apr 15;17(R1):R76-83. Review."
            }, 
            {
                "PMID": "12196638", 
                "citation": "Rempe DA, Kent TA. Using bone marrow stromal cells for treatment of stroke. Neurology. 2002 Aug 27;59(4):486-7."
            }, 
            {
                "PMID": "16624956", 
                "citation": "Felling RJ, Snyder MJ, Romanko MJ, Rothstein RP, Ziegler AN, Yang Z, Givogri MI, Bongarzone ER, Levison SW. Neural stem/progenitor cells participate in the regenerative response to perinatal hypoxia/ischemia. J Neurosci. 2006 Apr 19;26(16):4359-69."
            }, 
            {
                "PMID": "15210522", 
                "citation": "Gordon PH, Yu Q, Qualls C, Winfield H, Dillon S, Greene PE, Fahn S, Breeze RE, Freed CR, Pullman SL. Reaction time and movement time after embryonic cell implantation in Parkinson disease. Arch Neurol. 2004 Jun;61(6):858-61."
            }, 
            {
                "PMID": "15720218", 
                "citation": "Kulbatski I, Mothe AJ, Nomura H, Tator CH. Endogenous and exogenous CNS derived stem/progenitor cell approaches for neurotrauma. Curr Drug Targets. 2005 Feb;6(1):111-26. Review."
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01740869"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Hospital Universitario Dr. Jose E. Gonzalez", 
            "investigator_full_name": "M.D Laura Villarreal Martinez", 
            "investigator_title": "Hematology Service", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Improvement in CARS evaluation", 
            "measure": "CARS improvement", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "source": "Hospital Universitario Dr. Jose E. Gonzalez", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hospital Universitario Dr. Jose E. Gonzalez", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}